Eva Sedlackova

List of Publications by Year in Descending Order

29 papers	6,203 citations	16 h-index	30 g-index
30 ext. papers	7,436 ext. citations	6.9 avg, IF	4.9 L-index

#	Paper	IF	Citations
29	Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. *Endocrine*, **2021**, 71, 502-513	4	11
28	Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors. *Anti-Cancer Drugs*, **2020**, 31, 216-222	2.4	3
27	ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. *Neuroendocrinology*, **2016**, 103, 186-94	5.6	324
26	ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. *Neuroendocrinology*, **2016**, 103, 172-85	5.6	612
25	ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. *Neuroendocrinology*, **2016**, 103, 125-38	5.6	264
24	ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. *Neuroendocrinology*, **2016**, 103, 153-71	5.6	712
23	ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas). *Neuroendocrinology*, **2016**, 103, 144-52	5.6	144
22	ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. *Neuroendocrinology*, **2016**, 103, 139-43	5.6	153
21	ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. *Neuroendocrinology*, **2016**, 103, 119-24	5.6	258
20	Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. *Endocrine-Related Cancer*, **2016**, 23, 191-9	5.7	142
19	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. *Annals of Oncology*, **2015**, 26, 1604-20	10.3	363
18	Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study.. *Journal of Clinical Oncology*, **2015**, 33, 4104-4104	2.2	2
17	Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged ≤65 vs. >65 years: Subgroup analyses from the CLARINET study.. *Journal of Clinical Oncology*, **2015**, 33, e15177-e15177	2.2	3
16	Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs).. *Journal of Clinical Oncology*, **2015**, 33, e15180-e15180	2.2	2
15	Relative risk of adverse events with lanreotide depot/autogel (LAN) vs. placebo (PBO) in patients with intestinal and pancreatic neuroendocrine tumors (NETs).. *Journal of Clinical Oncology*, **2015**, 33, e15181-e15181	2.2	2
14	Lanreotide depot/autogel (LAN) in intestinal and pancreatic neuroendocrine tumors (NETs) according to body mass index (BMI): Subgroup analyses from the CLARINET study.. *Journal of Clinical Oncology*, **2015**, 33, e15182-e15182	2.2	3
13	Effects of lanreotide autogel/depot (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study.. *Journal of Clinical Oncology*, **2015**, 33, 233-233	2.2	4

List of Publications

12	Effects of lanreotide autogel/depot (LAN) in patients with neuroendocrine tumors (NETs) age 65 or younger versus older than age 65: Subgroup analyses from the CLARINET study.. *Journal of Clinical Oncology*, **2015**, 33, 367-367	2.2	2
11	Lanreotide depot/autogel (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study.. *Journal of Clinical Oncology*, **2015**, 33, e15178-e15178	2.2	
10	Lanreotide in metastatic enteropancreatic neuroendocrine tumors. *New England Journal of Medicine*, **2014**, 371, 224-33	59.2	1070
9	Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study.. *Journal of Clinical Oncology*, **2014**, 32, 4107-4107	2.2	7
8	Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet, The*, **2013**, 381, 805-16	40	1293
7	The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. *Breast Cancer Research and Treatment*, **2012**, 131, 295-306	4.4	8
6	Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8□1 years median follow-up. *Lancet Oncology, The*, **2011**, 12, 1101-8	21.7	298
5	Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. *Annals of Oncology*, **2009**, 20, 1489-1498	10.3	136
4	Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. *Clinical Trials*, **2009**, 6, 272-87	2.2	31
3	Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. *Journal of Clinical Oncology*, **2008**, 26, 5569-75	2.2	262
2	The role of FDG-PET/CT in the detection of recurrent colorectal cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2006**, 33, 779-84	8.8	88
1	Aleukemic granulocytic sarcoma with AML1/ETO fusion gene expression and clonal T cell populations. *Leukemia Research*, **2001**, 25, 1137-42	2.7	6